MX2021001574A - Vesiculas extracelulares para inhalacion. - Google Patents

Vesiculas extracelulares para inhalacion.

Info

Publication number
MX2021001574A
MX2021001574A MX2021001574A MX2021001574A MX2021001574A MX 2021001574 A MX2021001574 A MX 2021001574A MX 2021001574 A MX2021001574 A MX 2021001574A MX 2021001574 A MX2021001574 A MX 2021001574A MX 2021001574 A MX2021001574 A MX 2021001574A
Authority
MX
Mexico
Prior art keywords
vesicles
lung
exosomes
deliver
inhalation
Prior art date
Application number
MX2021001574A
Other languages
English (en)
Inventor
Gerard Bernard Mccauley
Original Assignee
Omnispirant Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omnispirant Ltd filed Critical Omnispirant Ltd
Publication of MX2021001574A publication Critical patent/MX2021001574A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Manufacturing & Machinery (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Las vesículas, que incluyen los exosomas, que tienen un recubrimiento de un polímero neutro hidrófilo, tal como el PEG, tienen una mayor capacidad de formar una suspensión o coloide en comparación con las vesículas no recubiertas. Esto permite que las vesículas recubiertas se usen para formar gotas de aerosol de manera que se pueda usar una formulación líquida que contenga vesículas en un nebulizador para su administración por inhalación. Tales vesículas recubiertas también pueden atravesar el moco y pueden suministrar su carga a las células pulmonares. Los exosomas de las células madre mesenquimales pueden suministrar proteínas, miR, ARNm y otras secuencias de ácidos nucleicos adicionales a las células pulmonares, lo que proporciona una terapia génica regenerativa para la FQ, el cáncer de pulmón con EPOC y otras enfermedades pulmonares.
MX2021001574A 2018-08-10 2019-08-09 Vesiculas extracelulares para inhalacion. MX2021001574A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18188591 2018-08-10
EP19154302 2019-01-29
PCT/EP2019/071511 WO2020030817A1 (en) 2018-08-10 2019-08-09 Extracellular vesicles for inhalation

Publications (1)

Publication Number Publication Date
MX2021001574A true MX2021001574A (es) 2021-07-15

Family

ID=67766129

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001574A MX2021001574A (es) 2018-08-10 2019-08-09 Vesiculas extracelulares para inhalacion.

Country Status (14)

Country Link
US (1) US12029821B2 (es)
EP (1) EP3833331A1 (es)
JP (1) JP7480143B2 (es)
KR (1) KR20210042351A (es)
CN (1) CN112566626A (es)
AU (1) AU2019316742A1 (es)
BR (1) BR112021002286A2 (es)
CA (1) CA3108605A1 (es)
CL (1) CL2021000334A1 (es)
IL (1) IL280658A (es)
MA (1) MA53273A (es)
MX (1) MX2021001574A (es)
SG (1) SG11202100870UA (es)
WO (1) WO2020030817A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111500607B (zh) * 2020-03-13 2022-05-03 首都医科大学附属北京口腔医院 种植体周围抗炎用融合基因、外泌体、生物涂料以及制备方法和应用
CN113384597A (zh) * 2020-03-13 2021-09-14 西比曼生物科技（上海）有限公司 含人体细胞衍生的细胞膜外囊泡的雾化吸入制剂、制法及其应用
EP4122475A4 (en) * 2020-03-16 2024-07-03 Exostemtech Co Ltd NOVEL USE OF A TANGENTIAL FLOW FILTRATION DEVICE TO PREPARE A FUNCTIONAL EXOSOME
EP4132539A4 (en) * 2020-04-06 2024-05-29 The Trustees Of Dartmouth College COMPOSITIONS AND METHODS FOR TREATING BACTERIAL INFECTIONS
CN113244173A (zh) * 2021-04-06 2021-08-13 浙江大学医学院附属邵逸夫医院 一种间充质干细胞外泌体改性修饰囊泡及其制备方法
CN115212230A (zh) * 2021-04-21 2022-10-21 西比曼生物科技（上海）有限公司 含有干细胞胞外囊泡的药物组合物及其在呼吸道炎症治疗中的应用
CN113522384A (zh) * 2021-07-06 2021-10-22 温州医科大学附属眼视光医院 一种微流控芯片及其制备与应用
CN114480260B (zh) * 2022-01-24 2024-02-09 同济大学 一种成体肺干细胞外泌体及其制备方法和应用
CN115181724A (zh) * 2022-06-10 2022-10-14 浙江工业大学 一种间充质干细胞来源的外泌体及其制备方法与应用
CN118574607A (zh) * 2022-12-30 2024-08-30 韩国科学技术研究院 表面修饰的植物来源细胞外囊泡以及利用其的靶向药物递送载体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2629502T3 (es) 2011-03-11 2017-08-10 Children's Medical Center Corporation Métodos y composiciones relacionados con exosomas de células madre mesenquimales
WO2013022786A2 (en) * 2011-08-05 2013-02-14 University Of Louisville Research Foundation, Inc. Microrna biomarkers
KR101993027B1 (ko) 2012-04-03 2019-09-30 레뉴런 리미티드 줄기 세포 마이크로입자
US20150216892A1 (en) * 2012-08-03 2015-08-06 Aptamir Therapeutics, Inc. Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
JP6137894B2 (ja) * 2013-03-22 2017-05-31 国立大学法人京都大学 リポソーム−エキソソームハイブリッドベシクル及びその調製法
WO2015002956A1 (en) 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
MX2017015962A (es) * 2015-06-10 2018-07-06 Univ Texas Uso de exosomas para el tratamiento de enfermedades.
WO2017075708A1 (en) 2015-11-05 2017-05-11 Exerkine Corporation Exosomes useful to treat cystic fibrosis
WO2018112557A1 (en) * 2016-12-23 2018-06-28 Altnia Operations Pty Ltd Methods and compositions for purification or isolation of microvesicles and exosomes
CN107625727B (zh) * 2017-08-10 2020-01-10 中国人民解放军第三O二医院 一种地塞米松纳米脂质体的胶体水溶液及其制备方法和应用

Also Published As

Publication number Publication date
US12029821B2 (en) 2024-07-09
KR20210042351A (ko) 2021-04-19
JP7480143B2 (ja) 2024-05-09
CL2021000334A1 (es) 2021-06-18
EP3833331A1 (en) 2021-06-16
IL280658A (en) 2021-03-25
AU2019316742A1 (en) 2021-02-11
JP2021534237A (ja) 2021-12-09
US20210308067A1 (en) 2021-10-07
CA3108605A1 (en) 2020-02-13
SG11202100870UA (en) 2021-02-25
CN112566626A (zh) 2021-03-26
BR112021002286A2 (pt) 2021-05-04
MA53273A (fr) 2021-06-16
WO2020030817A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
MX2021001574A (es) Vesiculas extracelulares para inhalacion.
Hassanzadeh et al. Mesenchymal stem/stromal cell-derived exosomes in regenerative medicine and cancer; overview of development, challenges, and opportunities
Hickey Back to the future: inhaled drug products
Nielsen et al. Pulmonary gene silencing in transgenic EGFP mice using aerosolised chitosan/siRNA nanoparticles
Ruigrok et al. Pulmonary administration of small interfering RNA: The route to go?
JP2020519648A5 (es)
Di Gioia et al. Nanocomplexes for gene therapy of respiratory diseases: Targeting and overcoming the mucus barrier
Kang et al. The therapeutic effects of human mesenchymal stem cells primed with sphingosine-1 phosphate on pulmonary artery hypertension
US20230105186A1 (en) Nanoparticle Modification of Human Adipose-Derived Mesenchymal Stem Cells for Treating Brain Cancer and Other Neurological Diseases
AU2017354275B2 (en) Foam for pulmonary drug delivery
US20220218733A1 (en) Therapeutic pharmaceutical composition for cancer including mirna
Mehta et al. miRNA nanotherapeutics: potential and challenges in respiratory disorders
Dua et al. Targeting microRNAs using nanotechnology in pulmonary diseases.
CN113905724A (zh) 包含线粒体的雾化组合物及其使用方法
Kaur et al. Advanced aerosol delivery devices for potential cure of acute and chronic diseases
Sahu et al. Strategic developments & future perspective on gene therapy for breast cancer: role of mTOR and Brk/PTK6 as molecular targets
MX2021001423A (es) Vectores virales encapsulados en polimero para terapia genica.
Andre et al. Characterization and comparison of two novel nanosystems associated with siRNA for cellular therapy
Koli et al. SiRNA-based therapies for pulmonary diseases
Tang et al. Effective delivery of osteopontin small interference RNA using exosomes suppresses liver fibrosis via TGF-β1 signaling
Lewis et al. Optimization of ionizable lipids for aerosolizable mRNA lipid nanoparticles
EA202190446A1 (ru) Внеклеточные везикулы для ингаляции
US20240009221A1 (en) Pharmacologic approach for suppression of coronaviruses
Trapani et al. Nanocarriers for respiratory diseases treatment: recent advances and current challenges
Chua et al. Carbonate apatite-facilitated intracellular delivery of c-ROS1 small interfering RNA sensitises MCF-7 breast cancer cells to cisplatin and paclitaxel